Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pvs230D1-EPA/Matrix-M Phase 1 in Healthy Adults
NCT05913973Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2023
- Primary completion
- Nov 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of Pvs230D1-EPA in malaria (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Incidence and severity of local and systemic adverse events (AEs) or serious adverse events (SAEs). Started Aug 2023; status: completed.
02
Drugs
Pvs230D1-EPA
03
Conditions
malaria
Beyond the preview
Go deeper on NCT05913973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05913973.